Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine.
In this pilot study of the effects of interferon alfa in 10 anti-HIV positive, chronic hepatitis B patients treated with zidovudine (AZT), tolerance to interferon was good and similar to that in anti-HIV negative patients. After treatment, the HIV stage and CD4 lymphocyte count were unchanged. In two patients hepatitis B virus (HBV)-DNA and hepatitis B e antigen (HBeAg) disappeared and the serum alanine aminotransferase (ALT) returned to normal; loss of hepatitis B surface antigen (HBsAg) with absence of histopathological activity was observed after treatment in one of these patients. These preliminary results need to be confirmed by a larger study.
Marcellin
P
P
Service d'Hépatologie, Hôpital Beaujon, Clichy, France.
Boyer
N
N
Colin
J F
JF
Martinot-Peignoux
M
M
Lefort
V
V
Matheron
S
S
Erlinger
S
S
Benhamou
J P
JP
D000328:Adult; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006679:HIV Seropositivity / Q000150:complications / Q000628:therapy*; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D015215:Zidovudine / Q000627:therapeutic use*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D015215:Zidovudine